COVID-19

[Molecular Psychiatry] Acid sphingomyelinase cleaves sphingomyelin into the highly lipophilic ceramide, which forms large gel-like rafts/platforms in the plasma membrane. The authors showed that SARS-CoV-2 uses these platforms for cell entry.

[American Journal of Gastroenterology] The authors evaluated adverse events after messenger RNA vaccination in 246 adults with inflammatory bowel disease participating in a longitudinal vaccine registry.

[Nature Medicine] Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients.

[Cell Discovery] The authors presented both single-cell TCR-seq and RNA-seq to analyze the dynamics of TCR repertoire and immune metabolic functions of blood T cells collected from recently discharged COVID-19 patients.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists assessed the effect of different adjuvants on human monocyte-derived dendritic cells and their ability to polarize innate and adaptive immune responses.

[Enochian BioSciences, Inc.] Enochian BioSciences, Inc. announced the completion of a Pre-Investigational New Drug process for ENOB-HB-01, a novel approach to potentially eliminate HBV-infected liver cells with an innovative “Hijack RNA” strategy that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection and liver disease.